Stock Analiz

Haemonetics Corp. (HAE) financials: revenue, earnings and cash flow

Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026

Summary

Haemonetics’s revenue went from $886M in fiscal 2017 to $1.3B in fiscal 2026, growth of about 4.7% a year.

Net income in fiscal 2026 was $97M, a net margin of 7.3%; the best year in this period was 2025 with $168M.

Over the twelve months to September 26, 2026, revenue was $1.4B and net income $104M.

Free cash flow was $260M in fiscal 2026 and positive in 10 of the 10 years shown.

The diluted share count fell 8% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2017: $886M172018: $904M182019: $968M192020: $988M202021: $870M212022: $993M222023: $1.2B232024: $1.3B242025: $1.4B252026: $1.3B26$1.3B
Net income
2017: -$26M172018: $46M182019: $55M192020: $77M202021: $79M212022: $43M222023: $115M232024: $118M242025: $168M252026: $97M26$97M
Free cash flow
2017: $84M172018: $146M182019: $40M192020: $109M202021: $72M212022: $76M222023: $82M232024: $144M242025: $142M252026: $260M26$260M
EPS (diluted)
2017: $-0.51172018: $0.85182019: $1.04192020: $1.48202021: $1.55212022: $0.84222023: $2.24232024: $2.29242025: $3.31252026: $2.0526$2.05

Income statement

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$1.4B$1.3B$1.4B$1.3B$1.2B$993M$870M$988M$968M$904M$886M
Gross profit$824M$788M$749M$692M$615M$506M$398M$485M$418M$412M$378M
Operating income$177M$157M$222M$165M$156M$81M$90M$103M$84M$56M-$19M
Net income$104M$97M$168M$118M$115M$43M$79M$77M$55M$46M-$26M
EPS (diluted)$2.26$2.05$3.31$2.29$2.24$0.84$1.55$1.48$1.04$0.85$-0.51
R&D$62M$60M$63M$54M$50M$47M$33M$31M$36M$39M$38M
Revenue growth—−2.0%+4.0%+12.0%+17.7%+14.1%−11.9%+2.2%+7.0%+2.0%−2.5%

Cash flow

Fiscal yearTTM2026202520242023202220212020201920182017
Operating cash flow$345M$293M$182M$182M$273M$172M$109M$158M$159M$220M$160M
Capital spending-$47M-$33M-$39M-$38M-$191M-$97M-$37M-$49M-$119M-$75M-$76M
Free cash flow$298M$260M$142M$144M$82M$76M$72M$109M$40M$146M$84M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$100M$175M$225M$0$75M$0$0$175M$160M$100M$0
Stock-based pay$36M$34M$30M$28M$26M$24M$26M$20M$17M$13M$9M

Balance sheet

Fiscal yearTTM2026202520242023202220212020201920182017
Cash—$245M$307M$179M$284M$259M$192M$137M$169M$180M$140M
Debt—$1.3B$1.3B$874M$829M$836M$778M$442M$350M$254M$316M
Equity—$796M$821M$960M$818M$749M$732M$587M$668M$752M$740M
Total assets—$2.4B$2.5B$2.2B$1.9B$1.9B$1.8B$1.3B$1.3B$1.2B$1.2B
Shares (diluted)46M47M51M51M51M51M51M52M53M54M52M

Margins and returns

Fiscal yearTTM2026202520242023202220212020201920182017
Gross margin59.6%59.0%55.0%52.8%52.6%50.9%45.7%49.0%43.1%45.6%42.7%
Operating margin12.8%11.8%16.3%12.6%13.4%8.1%10.3%10.5%8.6%6.2%-2.2%
Net margin7.5%7.3%12.3%9.0%9.9%4.4%9.1%7.7%5.7%5.0%-3.0%
FCF margin21.6%19.5%10.5%11.0%7.0%7.6%8.2%11.1%4.2%16.1%9.4%
ROIC—5.7%8.2%7.0%7.7%3.5%4.7%8.8%6.1%4.3%-1.8%
ROE—12.2%20.4%12.2%14.1%5.8%10.9%13.0%8.2%6.1%-3.5%

Frequently asked questions

What is Haemonetics’s annual revenue?

$1.3B in fiscal 2026 and $1.4B over the twelve months to September 26, 2026.

How much profit does Haemonetics make?

Net income was $97M in fiscal 2026 (net margin 7.3%).

Is Haemonetics’s revenue growing?

No: revenue fell 2.0% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.